Equivalent cross-relaxation rate imaging and diffusion weighted imaging for early prediction of response to bevacizumab-containing treatment in colorectal liver metastases—preliminary study

详细信息    查看全文

• 作者：Shigeru Matsushima^a ; ^{smts@aichi-cc.jp} ; Takeshi Sato^b ; Hideyuki Nishiofuku^b ; Yozo Sato^a ; Shinichi Murata^a ; Yasutomi Kinosada^c ; Seiichi Era^d ; Yoshitaka Inaba^a
• 关键词：Equivalent cross-relaxation rate imaging ; Diffusion weighted imaging ; Bevacizumab-containing treatment ; Early prediction of response ; Necrosis
• 刊名：Clinical Imaging
• 出版年：2017
• 出版时间：January-February 2017
• 年：2017
• 卷：41
• 期：Complete
• 页码：1-6
• 全文大小：594 K
• 卷排序：41

文摘

To evaluate and compare the usefulness of equivalent cross-relaxation rate (ECR) imaging (ECRI) and diffusion-weighted imaging (DWI) in the early prediction of the response of bevacizumab-containing treatments of colorectal liver metastases.Methods and materialSeven patients received bevacizumab-containing treatments for colorectal liver metastases. Serial magnetic resonance imaging was performed to evaluate responses before and 2 weeks after starting chemotherapy. In the ECRI, we adopted the off-resonance technique for preferential saturation of immobile protons to evaluate the ECR values. A single saturation transfer pulse frequency was used at a frequency of 3.5 ppm downfield from the water resonance. In the DWI, the apparent diffusion coefficient (ADC) value commonly used with two b-values was acquired by using diffusion weightings of 0 and 800 s/mm2. The region of interest of the metastatic lesions in the liver was separately measured by ECRI and DWI. Tumor response was assessed by response evaluation criteria in solid tumors criteria 8 weeks after starting chemotherapy.ResultsIn this study, we had four responders and three nonresponders. There was a significant difference in the pretreatment ECR values between the responders and nonresponders (P=.01); there was no significant difference in the ADC values between the two groups. Analysis of the percentage difference between the pretreatment and post-treatment values, termed as percentage change, showed that there were no significant differences in the percentage change of the ADC values between both groups; however, the percentage change in the ECR value was significantly greater for the responders than for the nonresponders (−41.6%±17.1% vs. –12.9%±6.9%, respectively; P=.04).ConclusionThe pretreatment ECR value and percentage change of the ECR value 2 weeks after starting chemotherapy were useful parameters in the early prediction of response to bevacizumab-containing treatment in colorectal liver metastases.